[1]梁欣 韩江莉.多重共存病与心房颤动患者的关系及影响[J].心血管病学进展,2025,(2):102.[doi:10.16806/j.cnki.issn.1004-3934.2025.02.002]
　LIANG XinHAN Jiangli.The Relationship and Influence Between Multimorbidity and Atrial Fibrillation Patients[J].Advances in Cardiovascular Diseases,2025,(2):102.[doi:10.16806/j.cnki.issn.1004-3934.2025.02.002]
点击复制

多重共存病与心房颤动患者的关系及影响()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年2期
页码:
102
栏目:
综述
出版日期:
2025-02-25

文章信息/Info

Title:
The Relationship and Influence Between Multimorbidity and Atrial Fibrillation Patients
作者:
梁欣1; 2 韩江莉 1
(北京大学第三医院心内科,北京 100191;2.开滦总医院心内科,河北 唐山 063000)
Author(s):
LIANG Xin1; 2HAN Jiangli1
Department of Cardiology,Peking University Third Hospital,Beijing 100191 ,China; 2.Department of Cardiology,Kailuan General Hospital,Tangshan 063000,Hebei,China)
关键词:
心房颤动; 多重共存病; 并发症
Keywords:
Atrial fibrillation; Multimorbidity; Comorbidity
DOI:
10.16806/j.cnki.issn.1004-3934.2025.02.002
摘要:
心房颤动（AF）患病率呈逐渐上升的趋势，与许多其他共存病存在关联，这些疾病之间相互作用，导致AF合并多重共存病的情况十分普遍。因此准确识别AF的共存病，探讨多重共存病与AF的关系及影响，对于制定有效的AF管理治疗策略十分重要。合并多重共存病的AF患者属于高危复杂患者，为了给予这类患者良好有效的治疗和管理，应采用着眼于多重共存病整体的个体化综合治疗管理策略。再者，对这类患者制定的预后评估方案中，要注意自我健康状态评价的改善。然而，由于个体之间合并多重共存病的种类和模式存在较大差异，导致他们的治疗和管理仍存在很大困难，未来仍需更多研究进一步探索。
Abstract:
The prevalence of atrial fibrillation (AF) is gradually increasing. AF is associated with many other comorbidities,contributing to the emergence of multimorbidity. It is very common for AF patients to have multimorbidity. Therefore,accurately identifying the comorbidities of AF,investigating the relationship between multimorbidity and AF,understanding how multimorbidity influences AF,are essential for developing effective management and treatment strategies.AF patients with multimorbidity belong to high-risk patients. An individualized treatment strategy that focusing on multimorbidity is needed to provide effective management and treatment strategies for these patients. Furthermore,in the outcomes assessment strategy for AF patients with multimorbidity,the improvement of self-rated health should be noticed. Due to the significant differences in the patterns of multimorbidity among individual patients,there are still great difficulties in the treatment and management of AF patients with multimorbidity,and further researches are needed in the future

参考文献/References:

[1]. Kotalczyk A,Guo Y,Wang Y,et al. Impact of multimorbidity and polypharmacy on clinical outcomes of elderly chinese patients with atrial fibrillation[J]. J Clin Med,2022,11(5):1370.
[2]. Romiti GF,Corica B,Mei DA,et al. Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis:an analysis from the Prospective Global GLORIA-AF Registry[J]. BMC Med,2024,22(1):151.
[3]. Abu HO,Saczynski J,Mehawej J,et al,Multimorbidity,physical frailty,and self-rated health in older patients with atrial fibrillation[J]. BMC Geriatr,2020,20(1):343.
[4]. Lobeek M,Middeldorp ME,van Gelder IC,et al. Multimorbidity in patients with atrial fibrillation[J]. Open Heart,2024,11(1):e002641.
[5]. Wang J,Yang YM,Zhu J,et al. Multimorbidity and polypharmacy in Chinese emergency department patients with atrial fibrillation and impacts on clinical outcomes[J]. Front Cardiovasc Med,2022,9:806234.
[6]. van Deutekom C,Geelhoed B,van Munster BC,et al. Cardiovascular and renal multimorbidity increase risk of atrial fibrillation in the PREVEND cohort[J]. Open Heart,2023,10(2):e002315.
[7]. di Benedetto L,Michels G,Luben R,et al. Individual and combined impact of lifestyle factors on atrial fibrillation in apparently healthy men and women:the EPIC-Norfolk prospective population study[J]. Eur J Prev Cardiol,2018,25(13):1374-1383.
[8]. Park JS,Yang PS,Kim D,et al. All-cause death and major adverse events in atrial fibrillation with frailty:observations from the korea national health insurance service data[J]. Rev Cardiovasc Med,2024,25(2):52.
[9]. Proietti M,Romiti GF,Raparelli V,et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation:A systematic review and meta-analysis of 1,187,000 patients[J]. Ageing Res Rev,2022,79:101652.
[10]. Shantsila E,Choi EK,Lane DA,et al. Atrial fibrillation:comorbidities,lifestyle,and patient factors[J]. Lancet Reg Health Eur,2024,37:100784.
[11]. Bhattarai U,Bashyal B,Shrestha A,et al. Frailty and chronic diseases:a bi-directional relationship[J]. Aging Med (Milton),2024,7(4):510-515.
[12]. Diemberger I,Fumagalli S,Mazzone AM,et al. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing:an ETNA-AF-Europe sub-analysis[J]. Europace,2022,24:1404-411.
[13]. Kozie? M,Simovic S,Pavlovic N,et al. Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation:insights from the BALKAN-AF survey[J]. Ann Med,2021,53(1):17-25.
[14]. Kirchhof P ,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J,2016,37(38):2893-2962.
[15]. Wilkinson C,Wu J,Clegg A,et al. Impact of oral anticoagulation on the association between frailty and clinical outcomes in people with atrial fibrillation:nationwide primary care records on treatment analysis[J]. Europace,2022,24:1065-1075.
[16]. Ma CS,Wu SL,Liu SW,et al; Chinese Society of Cardiology,Chinese Medical Association; Heart Rhythm Committee of Chinese Society of Biomedical Engineering. Chinese Guidelines for the diagnosis and management of atrial fibrillation[J]. J Geriatr Cardiol,2024,21(3):251-314.
[17]. Chamberlain AM,Alonso A,Gersh BJ,et al. Multimorbidity and the risk of hospitalization and death in atrial fibrillation:a population-based study[J]. Am Heart J,2017,185:74-84.
[18]. Kuipers MF,Laurila R,Remy ML,et al. Exploring diet-based treatments for atrial fibrillation:patient empowerment and citizen science as a model for quality-of-life-centered solutions[J]. Nutrients,2024,16(16):2672.
[19]. Reinwarth AC,Wicke FS,Rückert KK,et al. Change of self-rated physical health predicts mortality in aging individuals:results of a population-based cohort study[J]. Arch Public Health,2024,82(1):130.
[20]. Institute of Medicine (US) Committee on Assessing Interactions Among Social,Behavioral,and Genetic Factors in Health. Genes,Behavior,and the Social Environment:Moving Beyond the Nature/Nurture Debate[R].Washington (DC):National Academies Press(US),2006.
[21]. Alimujiang A,Strecher V,McLean K,et al. Decomposing the association of psychosocial wellbeing with all-cause mortality:the mediating role of physical health and lifestyle factors[J]. Soc Psychiatry Psychiatr Epidemiol,Jul 23.doi: 10.1007/s00127-024-02717-y.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(2):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(2):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(2):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(2):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

更新日期/Last Update: 2025-03-11